Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03078322 · ClinicalTrials.gov registry record · Phase 2
AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
A Phase 2 study, sponsored by VistaGen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT03078322 is a Phase 2 study that has completed, run by VistaGen Therapeutics. The registered enrollment target is 180 participants.
The verdict
NCT03078322, a Phase 2 study, has completed, sponsored by VistaGen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The study will evaluate the safety and efficacy of AV-101.
Interventions
- DRUG Placebo
- DRUG AV-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2018-03-05 |
| Est. Completion | 2019-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03078322
The ClinicalTrials.gov registry entry for NCT03078322 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VistaGen Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03078322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03078322 about?
NCT03078322 is a clinical study titled "AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression". The study will evaluate the safety and efficacy of AV-101.
What is the current status of trial NCT03078322?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2018-03-05. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT03078322?
The interventions under investigation include: Placebo (DRUG), AV-101 (DRUG).
Who is sponsoring clinical trial NCT03078322?
This trial is sponsored by VistaGen Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.